SmartPeptide
InflammationStrong human clinical evidence

Thymosin Alpha-1

Immunomodulatory peptide approved in some countries (e.g., for hepatitis B). Studied in immune modulation contexts.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

Approved in many countries (e.g., for chronic hepatitis B and as an adjunct in some immune-compromised states). Multiple clinical trials support immune-modulatory effects.

What's still experimental

Off-label uses (general immune support, COVID, oncology adjunct) have mixed and evolving evidence.

Anecdotal / community reports

Reports of fewer infections during cycles are common but not controlled.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

Live research

Updated hourly · sourced from PubMed + ClinicalTrials.gov
PubMed papers
858
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
10
63 total registered

Known risks

Should only be used under licensed clinical supervision.

Reported side effects

Generally well tolerated in approved indications.

What requires medical supervision

Should only be used under licensed clinical supervision. Drug interactions and immune-modulation effects warrant monitoring.

Questions for your clinician

  • Is this approved or off-label for my situation?
  • What baseline immune labs should we check?
  • How will we measure benefit objectively?

Editorially curated references